Definium Therapeutics (DFTX) Short-term Investments (2025 - 2026)
Definium Therapeutics (DFTX) reported Short-term Investments of $110.9 million for Q1 2026, down 14.42% year-over-year from $129.6 million in Q1 2025, and down 27.87% quarter-over-quarter from $153.8 million in Q4 2025.
Definium Therapeutics (DFTX) Short-term Investments (2025 - 2026) Analysis & Trends
Definium Therapeutics (DFTX) has 2 years of Short-term Investments data on file, last reported at $110.9 million in Q1 2026.
- Short-term Investments for Q1 2026 came in at $110.9 million, down 14.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $110.9 million (down 14.42% YoY), and the FY2025 annual result was $153.8 million, changed N/A from the prior year.
- Short-term Investments fell to $110.9 million in Q1 2026 per DFTX's latest filing, from $153.8 million in the prior quarter.
- Over five years, Short-term Investments peaked at $189.1 million in Q3 2025 and troughed at $110.9 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Definium Therapeutics | 2.46 Bn | 2.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 110.90 Mn |
| Dec 31, 2025 | 153.76 Mn |
| Sep 30, 2025 | 189.10 Mn |
| Jun 30, 2025 | 149.60 Mn |
| Mar 31, 2025 | 129.59 Mn |